Recent Updates
Recently added Catalysts
HLF Positive Sentiment

Herbalife Announces $250 Million Share Repurchase Program

Tuesday, September 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Herbalife Ltd. has announced a $250 million share repurchase program authorized by its Board of Directors. This initiative is set to take place over the next three years and reflects the company's confidence in its business strategy and financial outlook. The move is aimed at creating long-term value for shareholders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Herbalife's Board shows confidence in the company's strategy.
  • The share repurchase program aims to create long-term value.
  • The company expects to generate sustainable free cash flow.

Full Press Release Details

LOS ANGELES--(BUSINESS WIRE)--Herbalife Ltd. (NYSE: HLF) [“the Company”], a premier health and wellness company, community and platform, today announced its Board of Directors has authorized the repurchase of up to $250 million of the Company’s outstanding common stock over 3 years. The new authorization reflects the Company’s confidence in its business strategy, financial outlook and ability to generate sustainable free cash flow, while providing an additional avenue to create long-term value

Frequently Asked Questions

What is the amount of Herbalife's share repurchase program?

Herbalife's share repurchase program is authorized for up to $250 million.

Over what period will the share repurchase occur?

The share repurchase program will take place over three years.

What does the repurchase program reflect?

The program reflects the company's confidence in its business strategy and financial outlook.

What is the goal of the share repurchase program?

The goal is to create long-term value for shareholders.

ShareAdd on Google
Tags: HLF Viatris Investor Conferences Healthcare Herbalife share repurchase financial outlook long-term value
Last updated: Sep 8, 2026

Biotech snapshot

Cash runway
$371M liquidity · $0M/mo burn
Low dilution risk